Congress Acts to End PAMA Price Cutting Reign of Terror
After years of resistance, the lab industry’s hopes and prayers for relief from the flawed pricing scheme may soon be answered.
After years of resistance, the lab industry’s hopes and prayers for relief from the flawed pricing scheme may soon be answered.
Changes to PAMA reporting timelines and requirements, as well as payment cuts, are just some of the main takeaways labs should know about.
Legislation introduced last week would require the use of a more reliable representative sample to determine lab test reimbursement rates.
While this reimbursement rule has been in effect since 2018, it can still be quite confusing; this article provides a guide to the basics.
Move to exclude testimony regarding potential patient impact of lab deficiencies as hearsay is dismissed by the court.